Aprepitant CAS: 170729-80-3
MF: C23H21F7N4O3
MW: 534.43
A selective neurokinin-1 (NK-1) receptor antagonist.

Aprepitant (CAS 170729-80-3)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 110ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Aprepitant is rated 5.0 out of 5 by 1.
loading
5
1
4
0
3
0
2
0
1
0
Nombres Alternativos: 5-[[(2R,3S)-2-[(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one; Emend; MK-0869
Solicitud: Aprepitant is a selective neurokinin-1 (NK-1) receptor antagonist
Número de CAS: 170729-80-3
Pureza: ≥99%
Peso Molecular: 534.43
Fórmula Molecular: C23H21F7N4O3
Para Uso Exclusivo en Investigación. No está diseñado para uso en diagnosis o terapia.
* En el Certificado de Análisis específico de lote, puede encontrar información específica (como el contenido en agua).
loading

Aprepitant is a novel selective neurokinin-1 (NK-1) receptor antagonist. In vitro studies using human liver microsomes show that it is metabolized primarily by CYP3A4 with minor metabolism by CYP2C19 and CYP1A2.


References

1. Hale, J J., et al., 1998. Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. Journal of medicinal chemistry. 41(23): 4607-14. PMID: 9804700
2. Campos, D., et al., 2001. Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19(6): 1759-67. PMID: 11251007
3. Van Belle, Simon., et al., 2002. Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 94(11): 3032-41. PMID: 12115394
4. Majumdar, Anup K., et al., 2006. Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. Journal of clinical pharmacology. 46(3): 291-300. PMID: 16490805

Estado de Materia :
Solid
ALMACENAMIENTO :
Store at -20° C
Punto de Fusión :
242-250° C
Para Uso Exclusivo en Investigación. No está diseñado para uso en diagnosis o terapia.
PubChem CID :
SMILES :
C[[email protected]@H](O[[email protected]]1OCCN(CC2=NNC(=O)N2)[[email protected]]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F

Descargar SDS (MSDS)

CERTIFICADO DE ANÁLISIS

Necesita Adobe Acrobat Reader para ver de forma fiable,
imprimir y comentar el documento de PDF

Aprepitant (CAS 170729-80-3)  Menciones del Producto

Ver como otros han utilizado Aprepitant (CAS 170729-80-3). Haga click en la entrada de PubMed .

Citaciones 1 a 2 de un total de 2

PMID: # 27609608  Bayati, S. et al. 2016. Eur. J. Pharmacol. 791: 274-283.

PMID: # 32824729  Molecules.

Citaciones 1 a 2 de un total de 2
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 114ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 8ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;